Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Other solid neoplasm 1Head & Neck 1Endocrine 1Dermatologic 1CNS 1

Conditions

Sarcoma 2Uveal Melanoma 1Rhabdomyosarcoma 1Retinoblastoma 1Pituitary Diseases 1Osteosarcoma 1Neuroblastoma 1Mesothelioma 1Melanoma 1Medulloblastoma 1Laryngeal Diseases 1Glioma 1Colonic Neoplasms 1Cholangiocarcinoma 1Breast Neoplasms 1Adenoma, Islet Cell 1

Interventions

Vincristine 5Etoposide 5Carboplatin 5Melphalan 3Topotecan 2Platinum Compounds 2Drug Therapy 2Cyclophosphamide 2Cryotherapy 2pembrolizumab 1omburtamab I-131 1abemaciclib 1Wechsler Scales 1Watchful Waiting 1Thiotepa 1Surveys and Questionnaires 1Specimen Handling 1Observation 1Microscopy, Acoustic 1Memory and Learning Tests 1Magnetic Resonance Spectroscopy 1Lasers, Semiconductor 1Lasers 1LY2940680 1Hyperthermia, Induced 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Eye Enucleation 1Dynamic Contrast Enhanced Magnetic Resonance Imaging 1Doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Retinoblastoma × LY2940680 × 1 year × Clear all
NCT05199584 2026-03-05

A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations

Endeavor Biomedicines, Inc.

Phase 2 Completed
20 enrolled
CNSDermatologicEndocrineHead & NeckOther solid neoplasmSarcomaThoracic

Uveal Melanoma, Glioma, Adenoma, Islet Cell, Laryngeal Diseases, Medulloblastoma, Melanoma, Mesothelioma, Neuroblastoma, Pituitary Diseases, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡